Fig. 4: LASS2 inhibits EMT and ECM in liver cancer cell lines through the p53 signaling pathway.

A, B Representative western blot images (left) and quantification (right) of EMT markers (snail, slug, N-cadherin, E-cadherin, and vimentin) in (A) HepG2 and (B) HCCLM3 cell lines. C, D The expression of ECM markers (MMP2 and MMP9) were detected by western blotting and quantified by western blot analysis in HepG2 (C) and HCCLM3 (D) cells. E, F Representative western blot of cell-lysates from (E) HepG2 with WT p53 or (F) HCCLM3 with p53 mutant status, indicated that LASS2 overexpression inhibits p53 downstream EMT targets (slug, N-cadherin, and vimentin), at least in part, through the p53 signaling pathway (*P < 0.05, **P < 0.01, ***P < 0.001, as indicated).